Skip to content
conftrace_
2026 MLHC MLHC 2026

A Structure-Constrained Neural Simulator for Population PK under Regimen Shift (ConstrainNODE-PK)

Prospective dose selection requires simulating concentration distributions under regimens for which no concentrations have yet been observed. In this setting, success is not defined by low individual prediction error alone but by calibrated population simulation under regimen shift: a model can fit held-out individual observations yet still miscalibrate exposure distributions and underestimate high-exposure risk when the dosing schedule changes. We present ConstrainNODE-PK, a structure-constrained neural population pharmacokinetic simulator for intravenous bolus dosing under linear kinetics. The model expresses concentration as an exact superposition of dose events applied to a learned unit-dose impulse response, so transfer to a new regimen changes only the event sequence. The response is parameterized as a positive exponential mixture with a monotone residual neural ordinary differential equation, enforcing non-negativity, stability and monotone post-bolus decay; together with exact superposition, this gives exact dose proportionality while remaining flexible enough to capture one- to three-compartment-like behavior without per-compound compartment selection. We evaluate on six simulated settings and two public cohorts, using held-out subjects throughout and assessing both individualized prediction and population-level simulation calibration. The primary stress test is strict transfer from once-daily to three-times-daily dosing, with no target-regimen concentrations available at inference time. In this setting, ConstrainNODE-PK maintains near-nominal 95% prediction-interval coverage (95.6%), whereas a matched unconstrained dose-aware neural ordinary differential equation falls to 45.8%. Across settings, the model remains competitive with matched nonlinear mixed-effects references on individualized prediction and preserves near-nominal prior-predictive population calibration. Strict regimen-transfer evidence comes from controlled simulated intravenous-bolus setting

More from MLHC 2026

All MLHC 2026 papers →